FiercePharmaOriginal article
{"a":[{"_":"Ascendis to pay 20% Yuviwell royalties in patent settlement with BioMarin","$":{"href":"/pharma/biomarin-wins-20-royalties-ascendis-yuviwel-until-2030-end-global-patent-disputes","hreflang":"en"}}]}
YuviwelPositive
AI Analysis
Summary
BioMarin and Ascendis have settled patent disputes with Ascendis agreeing to pay 20% royalties on Yuviwel net sales through May 2030, retroactive to first commercial sales. The settlement resolves global patent litigation between the competitors.
Outcome Details
Patent settlement: Ascendis to pay 20% of Yuviwel net sales royalties to BioMarin from first commercial sales through May 2030
Importance:5/10
Sentiment:
0.60
patent settlementroyalty agreementlegal dispute resolutioncompetitive product
Read the original article
Published by FiercePharma on August 31, 2026 1:17 PM